Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
GlaxoSmithKline
The primary objective of this study is to evaluate the efficacy of GSK598809 compared to placebo for the prevention of relapse to smoking in recently abstinent smokers. Subjects who meet eligibility criteria will enter a 4-week open label treatment period during which they will receive nicotine replacement therapy (NRT). Subjects who have achieved at least one week of abstinence during the last week of an open label treatment period will be randomized to either GSK598809 or placebo in the double-blind treatment period and followed for another 12 weeks.
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
has smoked at least 10 cigarettes a day for at least 2 years
has had multiple previous attempts to quit smoking and relapsed to smoking.
generally healthy
You may not be if
cannot be using smokeless tobacco of any type or has tried to quit with medicine.
does not abuse alcohol or drugs
certain emotional problems being treated with medications
